News

LIVTENCITY is the first and only treatment approved in the country targeting the pUL97 kinase. The approval was based on the Phase III SOLSTICE trial results, which demonstrated

This move follows their initial collaboration partnership in January last year, which covered Southeast Asia (SEA) regions. The expansion into MEA will aid in increasing the availability of

This move is set to bolster Rosemont’s capabilities in developing a wider range of dosage forms and modified release oral liquids. Pharma-Data has been instrumental in creating value-added

The company will develop these therapies to target human leukocyte antigen (HLA) Class II (HLA-II) in oncology field. The funding will support Yellowstone in its operational build, progression

New investors Mubadala Capital and Exor Ventures spearheaded this oversubscribed round. The Series B extension also saw participation from Qatar Investment Authority, alongside current stakeholders including Abingworth and

This new treatment is specifically indicated as a monotherapy for paediatric patients aged one month to two years with IS, provided the potential benefits justify the risk of

This therapy is currently being developed to treat chronic myeloid leukemia (CML) as well as other hematological cancers. If Takeda exercises this option, the company will have the

The alliance will harness the potential of traditional medical compounds in the fight against bacterial infections. Quadram’s TraDIS-Xpress platform will be utilised to innovate antibacterial treatments by  studying

These treatments, known as Folding Interfering Degraders (FIDs), target the protein folding process to induce the degradation of cancer-related proteins. The collaboration will leverage Sibylla’s Pharmacological Protein Inactivation